PROFOUND MEDICAL CORP. Stock-Based Compensation
PROFOUND MEDICAL CORP. (PROF) reported Stock-Based Compensation of $1.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- PROFOUND MEDICAL CORP. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $874.00K, a 39.77% decline year-over-year.
- PROFOUND MEDICAL CORP. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.05M, a 5.97% increase year-over-year.
- PROFOUND MEDICAL CORP. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.38M, a 212.44% increase year-over-year.
- PROFOUND MEDICAL CORP. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.67M, a 176.32% increase year-over-year.
- PROFOUND MEDICAL CORP. share-based payment arrangement, noncash expense for fiscal 2025 was $5.49M, a 112.71% increase from fiscal 2024.
- PROFOUND MEDICAL CORP. share-based payment arrangement, noncash expense for fiscal 2024 was $2.58M, a 24.47% decline from fiscal 2023.
- PROFOUND MEDICAL CORP. share-based payment arrangement, noncash expense for fiscal 2023 was $3.42M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $874.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.92M 10-Q · filed 2026-08-06 | $3.30M derived: sum of 3 quarters · filed 2026-08-06 | $4.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.05M 10-Q · filed 2026-05-07 | $2.43M derived: sum of 2 quarters · filed 2026-05-07 | $4.10M derived: sum of 3 quarters · filed 2026-05-07 | $5.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.05M derived: sum of 2 quarters · filed 2026-03-05 | $4.50M derived: sum of 3 quarters · filed 2026-08-06 | $5.49M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.12M derived: sum of 2 quarters · filed 2026-08-06 | $4.11M 10-Q · filed 2025-11-13 | $4.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.44M 10-Q · filed 2026-08-06 | $2.88M derived: sum of 3 quarters · filed 2026-08-06 | $3.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $989.00K 10-Q · filed 2026-05-07 | $1.43M derived: sum of 2 quarters · filed 2026-05-07 | $2.04M derived: sum of 3 quarters · filed 2026-05-07 | $2.80M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $442.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.05M derived: sum of 2 quarters · filed 2026-03-05 | $1.81M derived: sum of 3 quarters · filed 2026-03-05 | $2.58M 10-K · filed 2026-03-05 |
| 2024-09-30 | $604.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.37M derived: sum of 2 quarters · filed 2025-11-13 | $2.14M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $768.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.53M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $767.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $3.42M 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |